Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches

Jun 4, 2021 | Press Releases

Treatment with INTASYL dual-targeting BRD4 and PD-1, elicits complete tumor responses and evidence of synergy in newly released in vivo study resultsData presented at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMARLBOROUGH, Mass., June 4, 2021...

Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 13, 2021 | Press Releases

MARLBOROUGH, Mass., May 13, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

May 11, 2021 | Press Releases

Data provide proof-of-concept for the application of INTASYL compounds as a way to unlock the potential of CAR-T cell therapy in solid tumorsData presented at the 24th Annual Meeting of the American Society of Gene & Cell TherapyMARLBOROUGH, Mass., May 11, 2021...

Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings

Apr 29, 2021 | Press Releases

MARLBOROUGH, Mass., April 29, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Apr 10, 2021 | Press Releases

Data presented at the AACR Annual Meeting 2021MARLBOROUGH, Mass., April 10, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi...

Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

Mar 25, 2021 | Press Releases

MARLBOROUGH, Mass., March 25, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...